<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757003</url>
  </required_header>
  <id_info>
    <org_study_id>SU-09112008-1299</org_study_id>
    <secondary_id>13335 (SQL 73498)</secondary_id>
    <nct_id>NCT00757003</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease</brief_title>
  <official_title>A Clinical Study of the TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Diseases for Non-Surgical Candidates Under the Physician Sponsored IDE.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE OF RESEARCH:

      Endovascular stent-graft repair of aortic pathologies is a minimally-invasive alternative to
      open surgery that may decrease morbidity and mortality, particularly in high risk patients.
      Optimal patient selection, based on pathology and anatomy, is being defined. Technically
      successful implantation requires adequate assessment of pathology and anatomy, and
      development and execution of novel and delicate procedures that resolve the pathology while
      minimizing morbidity and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESCRIPTION:

      There will be a maximum of 100 patients treated with the new device. You will be evaluated by
      your doctor to determine if you are able to participate in this research study. This
      evaluation will include reviewing your medical history, a physical examination, and special
      x-rays. These special x-rays are called CT scans and angiograms. Your doctor will explain
      what tests you will have done. A CT scan is a special x-ray that allows your doctor to see
      the size and shape of your aorta and your arteries. An angiogram uses a catheter (a hollow
      tube) that is placed into your arteries. Both tests use dye that can be seen on x-rays to see
      how the blood flows through your aorta and the surrounding arteries; for the CT scan it will
      be injected into a vein, and for the angiogram it is injected through the catheter into your
      arteries. These tests would be conducted whether or not you were participating in this
      research study. Your doctor will use this type of testing to determine if you are eligible to
      participate in this research study and as part of your follow-up care. Currently there are
      two aortic stent grafts manufactured by W.L. Gore &amp; Associates that are approved by the FDA
      for experimental use. Your doctor will determine which device is more appropriate to treat
      your condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Technically Successful Implant</measure>
    <time_frame>Day 0 to Day 30</time_frame>
    <description>The percentage of participants with technically successful implantation as assessed by the investigator is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of Participants Experiencing at Least One Endoleak Following Procedure</measure>
    <time_frame>Up to 60 months following procedure</time_frame>
    <description>Endoleak is persistent blood flow in the aneurysm sac.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>60 months</time_frame>
    <description>Overall survival is reported as the count of participants alive 60 months following implant procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Aneurysm, Dissecting</condition>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <arm_group>
    <arm_group_label>Treatment Arm - Placement of TAG device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A TAG device will be used to repair the pathology in the thoracic aorta</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Stent-graft repair of descending thoracic aorta</intervention_name>
    <description>A TAG device will be used to repair the pathology in the thoracic aorta</description>
    <arm_group_label>Treatment Arm - Placement of TAG device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should be poor or high risk open surgical candidates.

          2. Thoracic aortic disease deemed to warrant exclusion in order to prevent rupture or
             extension including dissection and transection.

          3. Anatomy meets TAG Endoprosthesis specification criteria.

          4. Minimum 2 cm non-aneurysmal segment proximal and distal to the aneurysm

               -  &lt;60 angle in the aortic arch may require additional length of non-aneurysmal
                  segment is the arch is included in the treatment segment.

          5. Ability to comply with protocol requirements including follow-up.

          6. Signed Informed Consent

        Exclusion Criteria:

          1. &gt;4mm aortic taper and inability to use devices of different diameters, to compensate
             for the taper, in the treatment area of the aorta.

          2. Significant thrombus at the proximal or distal implantation sites.

          3. Planned occlusion of the left carotid or celiac arteries, unless supplemental conduit
             or alternate perfusion routes for end organ(s) provided.

          4. Degenerative connective tissue disease, e.g. Marfan's or Ehler's Danlos Syndrome,
             unless the proximal and distal implantation sites of the TAG Endoprosthesis are
             located with in previous surgical grafts.

        6. Female of child bearing age with positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Yung-Ho Sze</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 1, 2017</results_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel Yung-Ho Sze</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Diseases</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data is made available upon request to colleagues conducting similar studies throughout the US.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment October 2000 - November 2007. Patients presenting or transferred to Stanford University Medical Center with thoracic aortic pathology deemed prohibitively high risk for open surgical repair.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm - Placement of TAG Device</title>
          <description>Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the pathology in the thoracic aorta. Pathology may include aneurysm, dissection, penetrating ulcer, pseudoaneurysm, false aneurysm, transection, mycotic aneurysm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgically explanted</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not implanted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm - Placement of TAG Device</title>
          <description>Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the pathology in the thoracic aorta. Pathology may include aneurysm, dissection, penetrating ulcer, pseudoaneurysm, false aneurysm, transection, mycotic aneurysm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Technically Successful Implant</title>
        <description>The percentage of participants with technically successful implantation as assessed by the investigator is reported.</description>
        <time_frame>Day 0 to Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - Placement of TAG Device</title>
            <description>Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the pathology in the thoracic aorta. Pathology may include aneurysm, dissection, penetrating ulcer, pseudoaneurysm, false aneurysm, transection, mycotic aneurysm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Technically Successful Implant</title>
          <description>The percentage of participants with technically successful implantation as assessed by the investigator is reported.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants Experiencing at Least One Endoleak Following Procedure</title>
        <description>Endoleak is persistent blood flow in the aneurysm sac.</description>
        <time_frame>Up to 60 months following procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - Placement of TAG Device</title>
            <description>A TAG device will be placed in the Aorta to treat the AAA. A TAG device will be used to repair the aneurysm in the thoracic aorta
Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the aneurysm in the thoracic aorta</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants Experiencing at Least One Endoleak Following Procedure</title>
          <description>Endoleak is persistent blood flow in the aneurysm sac.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is reported as the count of participants alive 60 months following implant procedure.</description>
        <time_frame>60 months</time_frame>
        <population>9 lost to followup, 4 withdrew, 2 explanted, 1 never implanted, all excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - Placement of TAG Device</title>
            <description>Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the pathology in the thoracic aorta. Pathology may include aneurysm, dissection, penetrating ulcer, pseudoaneurysm, false aneurysm, transection, mycotic aneurysm.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is reported as the count of participants alive 60 months following implant procedure.</description>
          <population>9 lost to followup, 4 withdrew, 2 explanted, 1 never implanted, all excluded</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm - Placement of TAG Device</title>
          <description>A TAG device will be placed in the Aorta to treat the AAA. A TAG device will be used to repair the aneurysm in the thoracic aorta
Endovascular Stent-graft repair of descending thoracic aorta: A TAG device will be used to repair the aneurysm in the thoracic aorta</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>angina</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel ischemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>change in mental status</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>paraplegia/paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis/Pneumonia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>lymphocele</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>procedural hemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>type I endoleak</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>type II endoleak</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>access failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>aortic diameter enlargement</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Sze, Principal Investigator</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-0728</phone>
      <email>dansze@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

